Billionaire Profile
Rajeev Juneja
Global Rank
#1519

Image: Unsplash Contributor | Unsplash License | via Unsplash

Rajeev Juneja

CEO, Phamaceuticals
INDIA
Real-Time Net Worth
$2.736B
Estimated based on Phamaceuticals stock value as of March 6, 2026
-0.2% (24h)
Age
58
Source
Phamaceuticals
Industry
Healthcare
Citizenship
INDIA

Biography

Rajeev Juneja, the Vice Chairman and Managing Director of Mankind Pharma, is a prominent figure in the Indian healthcare industry. With an estimated net worth of $3.2 Billion as of September 2024, his wealth stems from his pivotal role in founding and developing Mankind Pharma, one of India's leading pharmaceutical companies. His career exemplifies the power of entrepreneurship, starting from modest beginnings to becoming a key player in the pharmaceutical sector. Juneja's leadership has been crucial in the company's growth and expansion, marked by strategic moves like the 2023 IPO and the 2024 acquisition of Bharat Serums and Vaccines, showcasing his commitment to innovation and market leadership. His focus on maintaining a 'startup culture' within a large corporation demonstrates a unique approach to business.

Fact Checked
Verified by Editorial Team
Live Data
Updated 3/6/2026

Wealth Over Time

In-Depth Profile

Early Life

Rajeev Juneja was born in New Delhi, India, on July 28, 1965. He co-founded Mankind Pharma in 1995 with his elder brother, Ramesh Juneja. From humble beginnings, Rajeev and Ramesh started their entrepreneurial journey with a modest capital of Rs 50 lakh and a small team of 20 employees. Their initial operations were limited to just two states, but their vision and dedication quickly propelled the company to national prominence.

Rise to Success

Mankind Pharma quickly grew to become the fourth-largest pharmaceutical company in India. Rajeev, as Vice Chairman and Managing Director, played a pivotal role in transforming Mankind Pharma from a small start-up into a major player in the pharmaceutical sector. Under his leadership, Mankind Pharma opened for its initial public offering worth INR 4,300 crore in May 2023.

Key Business Strategies

Rajeev Juneja credits Mankind Pharma's success to maintaining a "startup culture" even as the company grew into a billion-dollar corporation. He emphasizes the importance of being dynamic, understanding the needs of the hour, and being open to change. In 2024, the company made the bold move of acquiring Bharat Serums and Vaccines (BSV), expanding its reach in the healthcare sector.

Philanthropy

While specific amounts are difficult to pinpoint, Rajeev Juneja and Mankind Pharma are committed to corporate social responsibility. The company has engaged in various initiatives to improve healthcare access and support community development. Further details about the exact amounts spent on philanthropy requires deeper search. They have supported various charitable organizations and initiatives.

Career Milestones

1995

Co-founded Mankind Pharma

Co-founded the pharmaceutical company with his brother Ramesh Juneja.

2019

Developed Dydrogesterone

Mankind Pharma became the first Indian firm to develop Dydrogesterone, a drug for high-risk pregnancies.

2023

Mankind Pharma IPO

Oversaw the IPO of Mankind Pharma, marking a significant milestone.

2024

Acquisition of Bharat Serums and Vaccines

Led the acquisition of Bharat Serums and Vaccines, expanding the company's reach in the healthcare sector.

Philanthropy & Social Impact

Healthcare

Healthcare Support

$XB

Supporting various charitable organizations and initiatives aimed at promoting healthcare access.

Business Philosophy & Leadership

Notable Quotes

""In a fast-changing world, you cannot remain stationary. Every day is a new day. Be dynamic, understand the need of the hour, and be open to change.""

Leadership Principles

Adaptability

Embracing change and staying dynamic in a fast-evolving industry.

Customer Focus

Understanding the needs of the customer.

Innovation

Developing new products and expanding into new sectors.